Research Alliance Corporation III Class A Ordinary Shares

Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome

RACC has entered into a definitive business combination agreement with Oak Hill Bio to create a publicly listed company focused on the Phase 3 antisense therapy rugonersen for Angelman syndrome. The transaction is expected to provide approximately $175 million in gross proceeds, consisting of $75 million from RACC’s fully backstopped trust and a $100 million PIPE priced at $10.00 per share. The combined company is expected to close by year-end 2026 and trade on Nasdaq under the ticker symbol "OAKH", with Oak Hill CEO Josh Distler leading the new entity.

•2mo ago